bioMérieux S.A. (LON:0RUG)
London flag London · Delayed Price · Currency is GBP · Price in EUR
124.25
-0.05 (-0.04%)
At close: Aug 4, 2025
-0.04%
Market Cap12.79B
Revenue (ttm)3.29B
Net Income (ttm)357.42M
Shares Outn/a
EPS (ttm)3.01
PE Ratio35.79
Forward PE27.56
Dividend0.76 (0.61%)
Ex-Dividend DateJun 9, 2025
Volume5,617
Average Volume33,271
Open124.10
Previous Close124.30
Day's Range122.90 - 125.50
52-Week Range95.10 - 127.30
Beta0.48
RSI60.14
Earnings DateSep 4, 2025

About Despegar.com

bioMérieux S.A. develops and markets in vitro diagnostic solutions for infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemase producing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO or 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VI... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 1963
Employees 14,754
Stock Exchange London Stock Exchange
Ticker Symbol 0RUG
Full Company Profile

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.

Financial Statements

News

There is no news available yet.